Tokyo, March 31 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061101) titled 'Evaluation of Methylation-Based Circulating Tumor DNA and Biomarker Associations After Curative Treatment for Resectable Solid Tumors' on March 31.
Study Type:
Observational
Primary Sponsor:
Institute - National Cancer Center Hospital East
Condition:
Condition - Colorectal cancer/Ovarian cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To evaluate the performance of ctDNA analysis using an assay developed by BillionToOne, Inc. in predicting recurrence and prognosis in patients with solid tumors who have undergone curative-intent treatment
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with colorectal cancer and ovarian cancer who were enrolled in the MONSTAR-SCREEN-3 trial (Cohort B) and received curative treatment
Key exclusion criteria - 1.Cases with missing data required for this study.
2.Cases deemed inappropriate for enrollment in this study by the principal investigator.
3.Cases of withdrawal of consent or refusal of secondary use of specimens and/or data.
Target Size - 330
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 12 Month 20 Day
Date of IRB - 2026 Year 03 Month 24 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2030 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069594
Disclaimer: Curated by HT Syndication.
